Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
Clinical trial NCT03876587 · UNKNOWN
Trial details
- NCT number
- NCT03876587
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-01
- Primary completion
- 2019-10-01
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.